Literature DB >> 19636064

Role of leukemia cell invadosome in extramedullary infiltration.

Michael Stefanidakis1, Katja Karjalainen, Diana E Jaalouk, Carl G Gahmberg, Susan O'Brien, Renata Pasqualini, Wadih Arap, Erkki Koivunen.   

Abstract

Acute myelogenous leukemias (AMLs) are characterized by medullary and extramedullary invasion. We hypothesized that a supramolecular complex, the leukemia-cell invadosome, which contains certain integrins, matrix metalloproteinases (MMPs), and other as-yet unidentified proteins, is essential for tissue invasion and may be central to the phenotypic diversity observed in the clinic. Here we show that the specific binding of MMP-9 to leukocyte surface beta(2) integrin is required for pericellular proteolysis and migration of AML-derived cells. An efficient antileukemia effect was obtained by the hexapeptide HFDDDE, a motif of the MMP-9 catalytic domain that mediates integrin binding: HFDDDE prevented proMMP-9 binding, transmigration through a human endothelial cell layer, and extracellular matrix degradation. Notably, the functional protein anchorage between beta(2) integrin and proMMP-9 described in this study does not involve the enzymatic active sites targeted by known MMP inhibitors. Taken together, our results provide a biochemical working definition for the human leukemia invadosome. Disruption of specific protein complexes within this supramolecular target complex may yield a new class of anti-AML drugs with anti-invasion (rather than or in addition to cytotoxic) attributes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636064      PMCID: PMC2756207          DOI: 10.1182/blood-2008-04-148643

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  A molecular basis for integrin alphaMbeta 2 ligand binding promiscuity.

Authors:  Valentin P Yakubenko; Valeryi K Lishko; Stephen C-T Lam; Tatiana P Ugarova
Journal:  J Biol Chem       Date:  2002-10-10       Impact factor: 5.157

2.  Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins.

Authors:  Michael Stefanidakis; Mikael Bjorklund; Eveliina Ihanus; Carl G Gahmberg; Erkki Koivunen
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

3.  Intracellular and cell surface localization of a complex between alphaMbeta2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils.

Authors:  Michael Stefanidakis; Terhi Ruohtula; Niels Borregaard; Carl G Gahmberg; Erkki Koivunen
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

4.  Biopanning and rapid analysis of selective interactive ligands.

Authors:  R J Giordano; M Cardó-Vila; J Lahdenranta; R Pasqualini; W Arap
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

5.  Expression of a retinoic acid receptor gene in myeloid leukemia cells.

Authors:  C Wang; J E Curtis; M D Minden; E A McCulloch
Journal:  Leukemia       Date:  1989-04       Impact factor: 11.528

6.  The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9.

Authors:  Sylvie Monferran; Jenny Paupert; Stéphanie Dauvillier; Bernard Salles; Catherine Muller
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

7.  Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.

Authors:  Takuya Matsunaga; Naofumi Takemoto; Tsutomu Sato; Rishu Takimoto; Ikuta Tanaka; Akihito Fujimi; Takehide Akiyama; Hiroyuki Kuroda; Yutaka Kawano; Masayoshi Kobune; Junji Kato; Yasuo Hirayama; Sumio Sakamaki; Kyuhei Kohda; Kensuke Miyake; Yoshiro Niitsu
Journal:  Nat Med       Date:  2003-08-03       Impact factor: 53.440

8.  Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion.

Authors:  Mikael Björklund; Pia Heikkilä; Erkki Koivunen
Journal:  J Biol Chem       Date:  2004-04-30       Impact factor: 5.157

9.  MMP-9 sheds the beta2 integrin subunit (CD18) from macrophages.

Authors:  Tomás Vaisar; Sean Y Kassim; Ivan G Gomez; Pattie S Green; Sara Hargarten; Peter J Gough; William C Parks; Carole L Wilson; Elaine W Raines; Jay W Heinecke
Journal:  Mol Cell Proteomics       Date:  2008-12-30       Impact factor: 5.911

10.  Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester.

Authors:  S Tsuchiya; Y Kobayashi; Y Goto; H Okumura; S Nakae; T Konno; K Tada
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

View more
  23 in total

Review 1.  Is acute myeloid leukemia a liquid tumor?

Authors:  Maro Ohanian; Stefan Faderl; Farhad Ravandi; Naveen Pemmaraju; Guillermo Garcia-Manero; Jorge Cortes; Zeev Estrov
Journal:  Int J Cancer       Date:  2013-02-04       Impact factor: 7.396

2.  A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells.

Authors:  Estefanía Ugarte-Berzal; Elvira Bailón; Irene Amigo-Jiménez; Cidonia L Vituri; Mercedes Hernández del Cerro; María José Terol; Juan P Albar; Germán Rivas; José A García-Marco; Angeles García-Pardo
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

3.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.

Authors:  Roland B Walter; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Franklin O Smith; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Janet L Franklin; Craig A Hurwitz; Michael R Loken; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

4.  Evidence for organ-specific stem cell microenvironments.

Authors:  Barbara Ghinassi; Fabrizio Martelli; Maria Verrucci; Emanuela D'Amore; Giovanni Migliaccio; Alessandro Maria Vannucchi; Ronald Hoffman; Anna Rita Migliaccio
Journal:  J Cell Physiol       Date:  2010-05       Impact factor: 6.384

Review 5.  Rational therapeutic options for patients with myeloproliferative neoplasms.

Authors:  Ronald Hoffman
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

6.  Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides.

Authors:  Antoine Dufour; Stanley Zucker; Nicole S Sampson; Cem Kuscu; Jian Cao
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

7.  Targeting neuropilin-1 in human leukemia and lymphoma.

Authors:  Katja Karjalainen; Diana E Jaalouk; Carlos E Bueso-Ramos; Amado J Zurita; Akihiko Kuniyasu; Bedrich L Eckhardt; Frank C Marini; Benjamin Lichtiger; Susan O'Brien; Hagop M Kantarjian; Jorge E Cortes; Erkki Koivunen; Wadih Arap; Renata Pasqualini
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

8.  Myeloid sarcoma: current approach and therapeutic options.

Authors:  Batia Avni; Maya Koren-Michowitz
Journal:  Ther Adv Hematol       Date:  2011-10

9.  The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.

Authors:  V Novotny-Diermayr; S Hart; K C Goh; A Cheong; L-C Ong; H Hentze; M K Pasha; R Jayaraman; K Ethirajulu; J M Wood
Journal:  Blood Cancer J       Date:  2012-05-04       Impact factor: 11.037

10.  Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities.

Authors:  Margaret W Ndinguri; Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Trista K Robichaud; Gregg B Fields
Journal:  Molecules       Date:  2012-11-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.